A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma

Cancer Immunology, Immunotherapy

Volumn 51, Issue 1, 2002, Pages 33-44

  Takemura, Shin Ichi ^a   Kudo, Toshio ^b   Asano, Ryutaro ^b   Suzuki, Masanori ^a   Tsumoto, Kouhei ^b   Sakurai, Naoki ^a   Katayose, Yu ^a   Kodama, Hideaki ^a   Yoshida, Hiroshi ^a   Ebara, Shinji ^b   Saeki, Hisaaki ^b   Imai, Kohzoh ^c   Matsuno, Seiki ^a   Kumagai, Izumi ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabody; MUC1; Refolding system; Second generation bispecific antibody; Superantigen

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2; MUC1 ANTIBODY CD3 ANTIBODY CONJUGATE; STAPHYLOCOCCUS ENTEROTOXIN A; STAPHYLOCOCCUS ENTEROTOXIN A D227A; STAPHYLOCOCCUS ENTEROTOXIN A D227A MUC1 ANTIBODY CD3 ANTIBODY CONJUGATE; STAPHYLOCOCCUS ENTEROTOXIN A D227A MUSE11 SINGLE CHAIN FV ANTIBODY CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; EFFECTOR CELL; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MOLECULAR CLONING; MOLECULAR WEIGHT; MONONUCLEAR CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; BILE DUCT NEOPLASMS; CA-15-3 ANTIGEN; CARCINOMA; ENTEROTOXINS; ESCHERICHIA COLI; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; HYBRIDOMAS; IMMUNOTHERAPY; KILLER CELLS, LYMPHOKINE-ACTIVATED; MICE; MICE, SCID; MOLECULAR WEIGHT; NEOPLASM PROTEINS; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SUPERANTIGENS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036174958     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-001-0245-3     Document Type: Article

References (53)

1. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A
2. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu
3. Superantigen-targeted therapy: Phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies
4. Staphylococcal enterotoxin A-Fab fusion protein treatment-associated toxicities can be blunted by a mutation in the SEA MHC class II binding domain
5. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation
6. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplanted human Hodgkin's tumors
7. Immunohistological and immunochemical characterization of a novel pancreatic cancer-associated antigen MUSE11
8. Transfection of the human Muc 1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: Integration, expression and ultrastructural changes
9. Prevention of superantigen-induced tolerance in vivo by interleukin-2 treatment
10. Prevention of superantigen-induced down-regulation of T-cell mediated cytotoxic activity by IL-2 in vivo
11. Nucleotide sequence of the type A staphylococcal enterotoxin gene
12. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies
13. Kinetics of IL-2 and interferon-gamma production, expression of IL-2 receptors, and cell proliferation in human mononuclear cells exposed to staphylococcal enterotoxin A
14. Treatment of human B cell lymphoma xenografts with a CD3xCD19 diabody and T cells
15. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice
16. Immunotherapy of human colon cancer by antibody-targeted superantigens
17. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells
18. Superantigen-based immunotherapy: A phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer
19. Genetically engineered superantigens as tolerable antitumor agents
20. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinoma
21. Primary structure of the variable regions of a monoclonal antibody MUSE11 recognizing the tandem repeat domain of a mucin core protein, MUC1
22. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
23. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3xanti-CEA bispecific diabodies and B7xanti-CEA bispecific fusion proteins
24. 'Diabodies': Small bivalent and bispecific antibody fragments
25. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides
26. V beta-specific stimulation of human T cells by staphylococcal toxins
27. MUC1-specific targeting immunotherapy with bispecific antibodies: Inhibition of xenografted human bile duct carcinoma growth
28. Bispecific CD3xCD19 diabody for T cell-mediated lysis of malignant human B cells
29. Mutated SEA D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma (BDC)
30. Rapid and effcient site-specific mutagenesis without phenotypic selection
31. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
32. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice
33. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma
34. Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1
35. Class II MHC molecules are specific receptors for staphylococcus enterotoxin A
36. Localization of a site on bacterial superantigens that determines T cell receptor beta chain specificity
37. Engineering antibodies for therapy
38. MHC class II-independent, V beta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: Implications for use in treatment of human colon carcinoma
39. Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma
40. Crystal structure of a diabody, a bivalent antibody fragment
41. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1
42. SEA-scFv as a bifunctional antibody: Construction of a bacterial expression system and its functional analysis
43. A conformational epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies
44. Effective adoptive immunotherapy by T-LAK cells retargeted with bacterial superantigen-conjugated antibody to MUC1 in xenografted severe combined immunodeficient mice
45. Superantigens anergize cytokine production but not cytotoxicity in vivo
46. The development and extension of hepatohilar bile duct carcinoma. A three-dimensional tumor mapping in the intrahepatic biliary tree visualized with the aid of a graphics computer system
47. Construction of a diabody (small recombinant bispecific antibody) using a refolding system
48. Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma
49. OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties
50. Monoclonal antibody-based therapy
51. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimer
52. High level secretion of a humanized bispecific diabody from Escherichia coli